Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-07-25 23:56Group 1 - The company has approved the registration of medium-term notes and ultra-short-term financing bonds for its subsidiary, Guangzhou Pharmaceutical Co., Ltd., with a total amount of up to RMB 16 billion and RMB 20 billion respectively [1][2][3] - The registration for the medium-term notes is valid for two years and will be underwritten by China Merchants Bank [2] - The registration for the ultra-short-term financing bonds is also valid for two years and will be co-underwritten by China Merchants Bank and Industrial Bank [3] Group 2 - The company plans to invest RMB 14.985 billion as a limited partner in the establishment of the Guangzhou Traditional Chinese Medicine Fund Phase II, accounting for 99.90% of the total subscription amount [6][8] - The total scale of the fund is RMB 15 billion, with the management being handled by Guangzhou Traditional Chinese Medicine Capital Private Fund Management Co., Ltd., a subsidiary of the company's controlling shareholder [6][10] - The fund aims to invest in the biopharmaceutical sector, focusing on projects that align with the company's strategic development [16][25]